Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD

Mironid has successfully dosed the initial patient cohorts in a Phase 1 clinical trial of its first-in-class LoAc® small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD). The milestone advances the program into early-stage human testing, but no safety, efficacy, dosing, or financial data were disclosed.